Français
Search this site:
Symbol
Last
Change
IPN.PA
22.01 €
(0.00 % )
powered by Euronext©
The Group
Profile & Key figures
Message from the Chairman
Group history
R & D
R & D Homepage
Neurology
Endocrinology
Oncology
Primary care
Medicines
Governance
Board of directors
Executive committee
Board committees
Compensation of corporate officers
Business Development & Alliance Management
Ipsen worldwide
Targeted diseases
Neurology
Endocrinology
Oncology
Hematology
Primary care
Commitments
Vision, mission and values
Environment, health and safety
Ethics and compliance
Support to Patient Organizations
Solidarity
Fondation IPSEN
La Fondation Ipsen at a glance
Colloques, prizes, publications
Neurosciences
Alzheimer’s disease
Endocrinology
Cancer science
Longevity
Vascular
Partnerships
Salk Institute - Nature
Cell Press - Massachusetts General Hospital
Nature Publishing Group
Home
> Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia
Press release
22 June 2010
- Paris (France)
Encouraging results of GuidAge®, large scale European trial conducted in the prevention of Alzheimer’s Dementia
Download
Go to
Press room
Investor relations
Careers
Registration Document 2010
Download
